Medullary carcinoma of the thyroid with liver and lung metastases an assymptomatic patient with an active disease
Carcinoma medular de tiroides metastásico a hígado y pulmón paciente asintomática con enfermedad activa
Article Sidebar
PDF (Español (España))
FLIP
How to Cite
Cabal López, P. D. (2011). Medullary carcinoma of the thyroid with liver and lung metastases an assymptomatic patient with an active disease. Journal of Medicine and Surgery Repertoire, 20(2), 124–127. https://doi.org/10.31260/RepertMedCir.v20.n2.2011.686
Section
Case Reports
License terms
Main Article Content
Abstract
Medullary thyroid carcinoma is a rare malignancy with low prevalence. It arises from the parafollicular calcitoninproducing C-cells. lt may have an aggressive course spreading to regional lymph nodes and glandular tissue and distant metastases may involve bone, long and liver. Here, we present the case of a 26-year old female patient with such a malignancy with long and liver metastases. Despite surgical and pharmacological management her disease remains active with high calcitonin levels. Remarkably, scarce or no symptoms are noted.
Downloads
Download data is not yet available.
Article Details
References
1. Martin-Jean Schlumberger, Sebastiano Filetti Ian O.Hay. Non toxic diffuse and nodular goiter and thyroid neoplasia. Kronenberg: Williams Textbook of Endocrinology, 11th ed. 2008.
2. Lundgren CI, Delbridg L, Learoyd D, Robinson B. Surgical approach to medullary thyroid cancer. Arq Bras Endocrino! Metabol. 2007;51(5):818-24.
3. Kebebew E, ltuarte P H, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma:clinical characteristics, treatment, prognostic factors, and a comparison ofstaging systems. Cancer. 2000;88(5): 1139-48.
4. AI-Rawi M, Wheeler MH. Medullary tbyroid carcinoma update and present management controversies. Ann R Coll Surg Engl. 2006;88(5):433-8.
5. Bemier JJ, Rambaud JC, Cattan D, Prost A. Diarrhoea associated with medullary carcinoma ofthe thyroid. Gut. 1969;10(12):980-5.
6. Cohen MS, Phay JE, Albinson C et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg. 2002;235(5):648-54.
7. Rambaud JC, Jian R, Flourie B et al. Pathophysiological study ofdiarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role of shortened colonic transit time. Gut. 1988;29(4):537-43.
8. Sand M, Gelos M, Sand D et al. Serum calcitonin negative medullary thyroid carcinoma. World J Surg Oncol. 2006;4:97.
9. Barbet J, Campion L, Kraeber-Bodere F, Chata! JF. Prognostic impact of serum calcitonin andcarcinoembryonicantigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrino! Metab. 2005;90(11):6077-84.
10. Chow SM, Chao JK, Tiu SC, Choi KL, Tang DL, Law SC. Medullary thyroid carcinoma in Hong Kong Chinese patients. Hong Kong Med J. 2005;11(4):251-8.
11. Machens A, Hauptmann S, Dralle H. Medullarythyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissem:ination? JClin Endocrino] Metab. 2008;93(6):2234-8.
12. Brandao LG, Cavalheiro BG, Junqueira CR. Prognosticinfluence ofclinical and pathological factorsin medullary thyroid carcinoma: a study of53 cases. Clinics (Sao P aulo). 2009;64(9):849-56.
13. Fromigue J, De BT, Baudio E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases frommedullary thyroid carcinoma. J Clin Endocrino] Metab. 2006;91(7):2496-9.
14. Schott M, WillenbergHS, Sagert C et al. Identification ofoccult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery. Clin Endocrino! (Oxf). 2007;66(3):405-9.
15. Esik O, Szavcsur P, Szakall S Jr et al. Angiography effectively supports the diagnosis ofhepatic metastases in medullary thyroid carcinoma. Cancer. 2001;91(11):2084-95.
16. Isozaki T, Kiba T, Numata K et al. Medullary thyroid carcinoma with multiple hepatic metastases: treatrnent with transcatheter arterial embolization and percutaneous ethanol injection. Intem Med. 1999;38(1):17-21.
17. Giraudet AL, Vanel D, Leboulleux S et al. Imaging medullary thyroid carcinoma with persisten! elevated calcitonin levels. JClin Endocrino! Metab. 2007;92(11):4185-90.
18. MachensA, Schneyer U, Holzhausen HJ, Dralle H. Prospects ofrem:ission in medullary thyroid carcinoma according to basal calcitonin leve!. J Clin Endocrino! Metab. 2005;90(4):2029-34.
19. Miccoli P, Minuto MN, Ugolini C et al. Clinically unpredictable prognostic factors in the outcome ofmedullary thyroid cancer. Endocr Relat Cancer. 2007;14(4):1099-1105.
2. Lundgren CI, Delbridg L, Learoyd D, Robinson B. Surgical approach to medullary thyroid cancer. Arq Bras Endocrino! Metabol. 2007;51(5):818-24.
3. Kebebew E, ltuarte P H, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma:clinical characteristics, treatment, prognostic factors, and a comparison ofstaging systems. Cancer. 2000;88(5): 1139-48.
4. AI-Rawi M, Wheeler MH. Medullary tbyroid carcinoma update and present management controversies. Ann R Coll Surg Engl. 2006;88(5):433-8.
5. Bemier JJ, Rambaud JC, Cattan D, Prost A. Diarrhoea associated with medullary carcinoma ofthe thyroid. Gut. 1969;10(12):980-5.
6. Cohen MS, Phay JE, Albinson C et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg. 2002;235(5):648-54.
7. Rambaud JC, Jian R, Flourie B et al. Pathophysiological study ofdiarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role of shortened colonic transit time. Gut. 1988;29(4):537-43.
8. Sand M, Gelos M, Sand D et al. Serum calcitonin negative medullary thyroid carcinoma. World J Surg Oncol. 2006;4:97.
9. Barbet J, Campion L, Kraeber-Bodere F, Chata! JF. Prognostic impact of serum calcitonin andcarcinoembryonicantigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrino! Metab. 2005;90(11):6077-84.
10. Chow SM, Chao JK, Tiu SC, Choi KL, Tang DL, Law SC. Medullary thyroid carcinoma in Hong Kong Chinese patients. Hong Kong Med J. 2005;11(4):251-8.
11. Machens A, Hauptmann S, Dralle H. Medullarythyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissem:ination? JClin Endocrino] Metab. 2008;93(6):2234-8.
12. Brandao LG, Cavalheiro BG, Junqueira CR. Prognosticinfluence ofclinical and pathological factorsin medullary thyroid carcinoma: a study of53 cases. Clinics (Sao P aulo). 2009;64(9):849-56.
13. Fromigue J, De BT, Baudio E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases frommedullary thyroid carcinoma. J Clin Endocrino] Metab. 2006;91(7):2496-9.
14. Schott M, WillenbergHS, Sagert C et al. Identification ofoccult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery. Clin Endocrino! (Oxf). 2007;66(3):405-9.
15. Esik O, Szavcsur P, Szakall S Jr et al. Angiography effectively supports the diagnosis ofhepatic metastases in medullary thyroid carcinoma. Cancer. 2001;91(11):2084-95.
16. Isozaki T, Kiba T, Numata K et al. Medullary thyroid carcinoma with multiple hepatic metastases: treatrnent with transcatheter arterial embolization and percutaneous ethanol injection. Intem Med. 1999;38(1):17-21.
17. Giraudet AL, Vanel D, Leboulleux S et al. Imaging medullary thyroid carcinoma with persisten! elevated calcitonin levels. JClin Endocrino! Metab. 2007;92(11):4185-90.
18. MachensA, Schneyer U, Holzhausen HJ, Dralle H. Prospects ofrem:ission in medullary thyroid carcinoma according to basal calcitonin leve!. J Clin Endocrino! Metab. 2005;90(4):2029-34.
19. Miccoli P, Minuto MN, Ugolini C et al. Clinically unpredictable prognostic factors in the outcome ofmedullary thyroid cancer. Endocr Relat Cancer. 2007;14(4):1099-1105.